Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancers|July 30, 2020
Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry StudyPierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
British Journal of Haematology|April 2, 2023
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM studyStéphanie Dulucq, Françoise Rigal-Huguet, Franck E Nicolini, et al.
Cancers|September 9, 2020
Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML PatientsGabriel Etienne, Stéphanie Dulucq, Fréderic Bauduer, et al.
European Radiology|July 5, 2023
Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19Maéva Zysman, Julien Asselineau, Olivier Saut, et al.
Cancers|March 29, 2020
Outcome of Relapsed or Refractory <i>FLT3</i>-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry StudySarah Bertoli, Pierre-Yves Dumas, Emilie Bérard, et al.
Blood Advances|August 14, 2020
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcomePierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Cancer Medicine|May 14, 2021
Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitorsGabriel Etienne, Carole Faberes, Fréderic Bauduer, et al.
Blood Cancer Journal|May 31, 2024
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry studyCamille Gondran, Pierre-Yves Dumas, Emilie Bérard, et al.
American Journal of Hematology|November 18, 2024
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registriesChristian Récher, Pierre-Yves Dumas, Emilie Bérard, et al.
Pageof 2